Secondary hemorrhagic complications in aneurysmal subarachnoid hemorrhage: when the impact hits hard.

CONCLUSIONSSHCs present a rare sequela of SAH. Antiplatelet therapy during (but not before) SAH increases the risk of ventriculostomy-associated bleedings, but without further impact on the course and outcome of SAH. The use of thrombolytic agents for early effective anticoagulation carries relevant risk for major SHCs and poor outcome.
PMID: 30684947 [PubMed - as supplied by publisher]

Source: Journal of Neurosurgery - January 25, 2019 Category: Neurosurgery Authors: Darkwah Oppong M, Buffen K, Pierscianek D, Herten A, Ahmadipour Y, Dammann P, Rauschenbach L, Forsting M, Sure U, Jabbarli R Tags: J Neurosurg Source Type: research